Citius Pharmaceuticals Inc (NASDAQ:CTXR) does about 1.90M shares in volume on a normal day but saw 102331008 shares change hands in the recent trading day. The company now has a market cap of 14.10M USD. Its current market price is $1.37, marking an increase of 60.99% compared to the previous close of $0.85. The 52 week high reached by this stock is $26.25 whilst the lowest price level in 52 weeks is $0.65.
The consensus objective for the share price is $6.50, suggesting that the stock has a potential upside of 78.92% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 30, 2024 when D. Boral Capital upgraded the stock to “Buy” and issued a price target of $9.
The current price level is 69.33%, 54.42%, and -72.58% away from its SMA20, SMA50, and SMA200 respectively, with the CTXR price moving below the 50-day SMA on current market day. Citius Pharmaceuticals Inc (CTXR) stock is up 77.97% over the week and 95.99% over the past month. Its price is -65.75% year-to-date and -91.44% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.37 and 1.39 for whole year. Expected sales for next quarter are $5.76M, which analysts say will come at $7.67M for the current fiscal year and next year at $73.04M. In addition, estimates put the company’s current quarterly revenue at an average of $1.92M.
To reach the target analysts have set, the stock logically needs to grow 78.92 percent from here.
Outstanding shares total 10.29M with insiders holding 4.79% of the shares and institutional holders owning 6.24% of the company’s common stock. The company has a return on investment of -70.14% and return on equity of -60.06%. The forward price to earnings ratio is 1.62. The beta has a value of 0.88. Price to book ratio is 0.20.
